DIRECT DIAL: 212.451.2234


  June 10, 2021




U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549

Attention: Abby Adams and Tim Buchmiller
  Division of Corporation Finance,
  Office of Life Sciences


Re:Alzamend Neuro, Inc.
Registration Statement on Form S-1 (No. 333-255955)
Registration Statement on Form 8-A (No. 001- )        


Ladies and Gentlemen:


This letter will serve to withdraw the request for acceleration made yesterday by our client Alzamend Neuro, Inc.


Alzamend Neuro intends to seek acceleration of effectiveness of the above-referenced Registration Statements to 4:00 p.m., Eastern time, on Monday, June 14, 2021, or as soon as possible thereafter, and is re-submitting its request later this afternoon.


Thank you for your assistance.



  Very truly yours,

/s/ Spencer G. Feldman

  Spencer G. Feldman


cc:Mr. Stephan Jackman
Henry C.W. Nisser, Esq.